AstraZeneca PLC
AZN
$187.03
-$2.72-1.43%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 32.42% | -8.17% | 3.39% | -15.98% | 94.40% |
| Total Depreciation and Amortization | 16.75% | -24.47% | 11.52% | 8.18% | 103.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 53.97% | -187.10% | 300.93% | -77.05% | -106.58% |
| Change in Net Operating Assets | 16.74% | -243.83% | 342.03% | 19.01% | -21.71% |
| Cash from Operations | 43.42% | -54.38% | 51.62% | -8.81% | 27.73% |
| Capital Expenditure | 47.20% | -51.02% | -4.10% | -53.61% | 39.41% |
| Sale of Property, Plant, and Equipment | 166.67% | -- | -100.00% | 800.00% | -50.00% |
| Cash Acquisitions | 5.86% | 16.77% | -22.85% | 26.24% | -32.12% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -611.43% | 85.82% | 17.13% | -157.24% | -130.35% |
| Cash from Investing | -23.93% | 27.74% | 5.08% | -68.24% | -6.10% |
| Total Debt Issued | 527.27% | -187.50% | -154.66% | -41.40% | 292.13% |
| Total Debt Repaid | 95.45% | -2,166.67% | 19.13% | -35.29% | 28.57% |
| Issuance of Common Stock | -56.52% | 360.00% | 25.00% | -50.00% | -65.22% |
| Repurchase of Common Stock | -4,607.69% | 31.58% | -533.33% | 99.38% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -16,010.00% | 99.70% | -111,466.67% |
| Other Financing Activities | 75.51% | -9,700.00% | -50.00% | -101.92% | 552.17% |
| Cash from Financing | 108.14% | -58.32% | -500.19% | 119.14% | -303.43% |
| Foreign Exchange rate Adjustments | -550.00% | 133.33% | -141.38% | 16.00% | 140.98% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 176.24% | -327.29% | -42.58% | 922.07% | -122.33% |